Haleon plc (HLN)vsIndivior PLC Ordinary Shares (INDV)
HLN
Haleon plc
$9.12
+1.79%
HEALTHCARE · Cap: $40.34B
INDV
Indivior PLC Ordinary Shares
$35.43
+5.10%
HEALTHCARE · Cap: $4.45B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 755% more annual revenue ($11.03B vs $1.29B). INDV leads profitability with a 19.5% profit margin vs 15.1%. HLN trades at a lower P/E of 18.2x. HLN earns a higher WallStSmart Score of 63/100 (C+).
HLN
Buy63
out of 100
Grade: C+
INDV
Buy62
out of 100
Grade: C+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 92.0% YoY
Reasonable price relative to book value
Strong operational efficiency at 23.2%
Generating 1.3B in free cash flow
Strong operational efficiency at 46.1%
Earnings expanding 82.0% YoY
Conservative balance sheet, low leverage
19.2% revenue growth
Areas to Watch
Expensive relative to growth rate
0.6% revenue growth
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : HLN
The strongest argument for HLN centers on EPS Growth, Price/Book, Operating Margin. Profitability is solid with margins at 15.1% and operating margin at 23.2%.
Bull Case : INDV
The strongest argument for INDV centers on Operating Margin, EPS Growth, Debt/Equity. Profitability is solid with margins at 19.5% and operating margin at 46.1%. Revenue growth of 19.2% demonstrates continued momentum.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth.
Bear Case : INDV
The primary concerns for INDV are Free Cash Flow, Altman Z-Score.
Key Dynamics to Monitor
HLN profiles as a value stock while INDV is a growth play — different risk/reward profiles.
INDV carries more volatility with a beta of 1.17 — expect wider price swings.
INDV is growing revenue faster at 19.2% — sustainability is the question.
HLN generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
HLN scores higher overall (63/100 vs 62/100), backed by strong 15.1% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company, formed as a spin-off from GlaxoSmithKline, that specializes in delivering innovative health solutions through its extensive portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. With a focus on key health segments such as oral care, pain relief, and dietary supplements, Haleon leverages strong brand recognition to meet the evolving needs of consumers. The company's commitment to sustainability and continuous innovation positions it strategically for long-term growth, aimed at enhancing health outcomes and delivering shareholder value through targeted investments and ongoing product development.
Visit Website →Indivior PLC Ordinary Shares
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Indivior PLC, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company is headquartered in North Chesterfield, Virginia.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?